PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a co

Substitu	Substitute for form 1449/PTO			Complete if Known		
Assessed to total terror 19				Application Number 10/528,806-Conf. #6218		
INF	ORMATI	ON DIS	SCLOSURE	Filing Date	June 14, 2006	
ST	STATEMENT BY APPLICANT			First Named Inventor	Jan Meene	
• • • • • • • • • • • • • • • • • • • •				Art Unit	Not Yet Assigned 1644	
	(Use as man	y sheets as	necessary)	Examiner Name	Not Yet Assigned Sharon We	
Sheet	1	of	2	Attorney Docket Number	37998-237159	

U.S. PATENT DOCUMENTS						
Examiner Inklais*		C#-	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Otte No.1	Number-Kind Code ² (if known)			
75.	.W	AA*	US-5,674,902 A	10-07-1997	Szallasi Zoltan et al.	
	1	AB*	US-2005/0066381 A1	03-24-2005	Molkentin et al.	
		AC*	US-5,936,084	08-10-1999	Jirousek et al.	
$\overline{}$	7	AD*	US-5,344,841	09-06-1994	Jiang et al.	
		AE*	US-6,063,814	05-16-2000	Chang et al.	

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*		Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
		No.1	Country Code ³ -Number ⁴ -Kind Code ³ (if known)				T ⁶		
/S.\	Ν.	BA	DE-197 40 384 A1	03-11-1999					
	ī	BB	WO-97/07787	03-06-1997					
		BC	WO-2005/027629 A2	03-31-2005					
		BD	DE-39 24 538 A1	01-31-1991					
	1	BE	DE-696 00 784	04-08-1999					
	7	BF	DE-39 14764 A1	11-08-1990					

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw fine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filled after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Down at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patient documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner	201 144	Date	07/20/2007
Signature	/Sharon Wen/	Considered	07/30/2007

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete If Known		
				Application Number	10/528,806-Conf. #6218	
11	NFORMATION	I DI	SCLOSURE	Filing Date	June 14, 2006	
s	TATEMENT B	3Y /	APPLICANT	First Named Inventor	Jan Meene	
	(Use as many sheets as necessary)			Art Unit	Not Yet Assigned 1644	
				Examiner Name	Not Yet Assigned Sharon Wer	
Sheet	2	of	2	Attorney Docket Number	37998-237159	

		NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), vokume-issue number(s), publisher, city and/or country where published.					
/S.W./	CA	Menne, J. et al., "Protein kinase C alpha deficiency ameliorates the development of diabetic nephropathy in mice with streptozotocin-induced hpyerglycemia," Kidney and Blood Pressure Research, Bd. 24, Nr. 4-6, 2001, Seite 231					
	СВ	Menne, Jan et al., "Protein kinase C alpha deficiency ameliorates the development of diabetic nephropathy in mice with streptozotocin-induced hyperglycemia," Journal of the American Society of Nephrology, Bd. 12, Nr. Program and Abstract Issue, September 2001 (2001-09), Seite 151A					
	CC	Meier, Matthias et al., "Knockout of protein kinase C alpha protects against the development of albuminuria but not renal hypertrophy," Diabetes, Bd. 52, Nr. Supplement 1, 2003, Seite A50					
	CD	Kang, Ningling et al., "Differential expression of protein kinase C isoforms in streptozotocin- induced diabetic rats," Kidney International, Bd. 56, Nr. 5, November 1999					
	CE	Database Biosis 'Online' Biosciences Information Service, "Effect of cyclosporin-A on teh blood-retinal barrier permeabilty in streptozotocin-induced diabetes," XP002278387, Mediators of Inflammation, Bd. 9, Nr. 5, 2000, Seiten 243-248, ISSN: 0962-9351					
CF		Database Biosis 'Online' Biosciences Information Service, Philadelphia, PA, June 1998 (1998 06) Koya Daisuke et al., "Protein kinase C activation and the development of diabetic complications," XP002292425					
	CG	Database Biosis 'Online' Biosciences Information Service, Philadelphia, PA, October 23, 2001 (2001-10-23) Venugopal Senthil Kumar et al., "alpha-Tocopherol inhibits hyperglycemia-induced superoxide anion release from human monocytes via inhibition of PKC-alpha," XP008034017					
	СН	Database Medline 'Online' US National Library of Medicine (NLM), Bethesda, MD; September 1997 (1997-09) Hempel A. et al., "High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha," XP002292426					
	CI	Database Medline 'Online! US National Library of Medicine (NLM), Bethesda, MD, June 1996 (1996-06), Busuttil S J et al., "Antisense suppression of protein kinase C-alpha and -delta in vascular smooth muscle," XP002292427					
V	C1	Database Biosis 'Online! Biosciences Information Service, Philadelphia, PA, September 2001 (2001-09) Takahashi Tomoya et al., "Cyclosporin A promotes hair epithelial cell proliferation and modulates protein kinase C expression and translocation in hair epithelial cells," XP002292428					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DC 2 800500

Examiner Signature	/Sharon Wen/	Date Considered	07/30/2007

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.